BioSpace News Archive

IRADIMED CORPORATION (NASDAQ: IRMD) announced the retirement of Francis Casey, Vice President of Regulatory Affairs and Quality Assurance, effective June 30, 2020 after leading the Company’s regulatory efforts since 2004. IRADIMED appointed Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance, succeeding Mr. Casey, effective March 10, 2020

NEW HAVEN, Conn., Feb. 26, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at two upcoming healthcare investor conferences. Conference Presentation Details: Event: Cowen and Co. 40th Annual Health Care Conferen

CRANBURY, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference in Boston, MA on Tuesday, March 3, 2020 at 8:40 a.m. ET. A live audio webcast of the presentation can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events-and-presentations , and will be ar

Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the American Journal of Transplantation (AJT) published data on AlloSure’s ability to differentiate ambiguous rejections, titled “High levels of dd-cfDNA identifies patients with TCMR 1A

ALPHARETTA, Ga., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will present at two upcoming investor conferences in March 2020: Cowen 40th Annual Health Care Conference Company Presentation: Wednesday, March 4, 2020 at 8:00 am ET Boston, MA 32nd Annual ROTH Conference P

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, announced it will release financial results for the fourth quarter and full year ended December 31, 2019, after market close on Tuesday, March 10, 2020.

VANCOUVER, British Columbia, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms” or “PSF”), has completed its first shipment of cannabis under its supply agreement with Alberta Gaming, Liquor & Cannabis (AGLC). Pure Sunfarms’ recreational adult-use cannabis products will be available on Alberta’s only l

VANCOUVER , Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that its financial results for 2019 will be released on Tuesda

Feb. 26, 2020 12:00 UTC Two of three dose cohorts in Phase 2 CMV vaccine (mRNA-1647) dose-confirmation study completed enrollment; third and final cohort rapidly enrolling Up to $2 billion to invest, including cash and investments, financing proceeds and potentially available grants; reiterates guidance that net cash used in operating activities and for purchases of property and equipment is expected to total between $490 million and $510 million in 2020 CAMBRIDGE, Ma